Piper Jaffray analyst Charles Duncan is out with a research note on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), previewing the drug maker’s upcoming earnings announcement, as well as reiterating an Overweight rating on the stock, with a price target of $44, which represents a potential upside of 16% from where the stock is currently trading.

Duncan wrote, “On NUPLAZID 2017 revenues, we note there is a much larger range of analyst estimates, reflecting the uncertainty around even near-term penetration of this new market. As such, during the upcoming 4Q16 call, we do not necessarily expect ACADIA to provide revenue guidance for 2017. Our current estimate of $76M for the full year 2017 falls just below the Street consensus of $82M. During 2017, however, we anticipate significant growth in the number of new prescribers and the number of new ‘scripts per prescriber, especially as early adopters gain 3-6 months of experience with their first patients. In addition, by 2H17 we believe ACADIA’s expanded sales force focused on long-term care facilities may begin to impact the top line.”

According to TipRanks, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Charles Duncan has a yearly average return of 0.9% and a 47% success rate. Duncan has a 32% average return when recommending ACAD, and is ranked #2127 out of 4382 analysts.

Out of the 14 analysts polled in the past 12 months, 10 rate ACADIA Pharmaceuticals stock a Buy, while 4 rate the stock a Hold. With a return potential of 19%, the stock’s consensus target price stands at $45.30.